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Background: Acinetobacter baumannii has emerged as an opportunistic nosocomial pathogen causing infections
worldwide. One reason for this emergence is due to its natural ability to survive in the hospital environment, which may
be explained by its capacity to form biofilms. Cell surface appendages are important determinants of the A. baumannii
biofilm formation and as such constitute interesting targets to prevent the development of biofilm-related infections.
A chemical agent called virstatin was recently described to impair the virulence of Vibrio cholerae by preventing the
expression of its virulence factor, the toxin coregulated pilus (type IV pilus). The objective of this work was to investigate
the potential effect of virstatin on A. baumannii biofilms.
Results: After a dose–response experiment, we determined that 100 μM virstatin led to an important decrease (38%) of
biofilms formed by A. baumannii ATCC17978 grown under static mode. We demonstrated that the production of
biofilms grown under dynamic mode was also delayed and reduced. The biofilm susceptibility to virstatin was then
tested for 40 clinical and reference A. baumannii strains. 70% of the strains were susceptible to virstatin (with a decrease
of 10 to 65%) when biofilms grew in static mode, whereas 60% of strains respond to the treatment when their biofilms
grew in dynamic mode. As expected, motility and atomic force microscopy experiments showed that virstatin acts on
the A. baumannii pili biogenesis.
Conclusions: By its action on pili biogenesis, virstatin demonstrated a very promising antibiofilm activity affecting more
than 70% of the A. baumannii clinical isolates.
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Acinetobacter baumannii, a microorganism with a world-
wide epidemic spread, causes a wide range of infections,
including pneumonia and blood-stream infections. This
increasing threat in hospitals is mainly due to the occur-
rence of multidrug-resistant strains, associated with the
real problem of eradication in the hospital wards [1]. Bio-
film formation may facilitate the environmental survival
of A. baumannii by conferring resistance to antibiotics,
desiccation or nutritional stress and explain the success of
particular strains in hospitals [2,3]. Several factors have
been proved to play a role in this biofilm formation or
maturation, like the poly-β-(1–6)-N-acetyl glucosamine* Correspondence: emmanuelle.de@univ-rouen.fr
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article, unless otherwise stated.extracellular polysaccharide, the biofilm-associated pro-
tein, the autotransporter Ata or the systems of protein gly-
cosylation [4-7]. In addition, extracellular appendages are
often involved in different stages of bacterial biofilm [8] as
exemplified by the csuA/BABCDE chaperon-usher system,
coding for fimbriae, and required for initial steps of A.
baumannii biofilm development [6,9,10]. Recent findings
have also demonstrated that more than one cell surface
appendages system may be involved in the maintenance
of the biofilm structure, especially when the biofilm is
formed at the air-liquid interface [11]. Finally, the pre-
sence of a type IV pili system and its involvement in mo-
tility was recently described in A. baumannii [12]. It could
also play a role in biofilm development (initial adhesion,
microcolonies formation and in maturation, last step of
biofilm formation) as demonstrated for other bacterial
species [8,13]. Therefore, the contribution of extracellularentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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attractive as therapeutic targets [14].
In this study, we experienced this new approach by tes-
ting the use of the chemical agent virstatin. This small or-
ganic molecule has been demonstrated to inhibit Vibrio
cholerae virulence and its orogastric administration would
protect infant mice from V. cholerae intestinal coloni-
zation [15,16]. Virstatin acted in preventing expression of
the two major Vibrio cholerae virulence factors, cholera
toxin and the toxin coregulated pilus (a type IV pilus,
T4P). It would disrupt protein-protein interactions, i.e. the
dimerization of the transcriptional regulator ToxT, stop-
ping thus the activation of ctx and tcp genes [15,16].
We present here the efficacy of the virstatin as an inhibi-
tor of the pili system synthesis to prevent A. baumannii
biofilm formation.
Methods
Bacterial strains and MICs determination
We used A. baumannii ATCC 17978 and ATCC 19606 as
reference strains, as well as 38 clonally unrelated A.***
***
*
*
T= 1 h T= 6 h TB
A C
Figure 1 Effect of virstatin on biofilms formed by A. baumannii. A- Inh
static mode: percentages measured the 24 h-biofilm formation in presence
compared to biofilm formation without virstatin. Experiments were perform
mean). “***” for P < 0.0001 and “*” for P < 0.05, B- Effect on biofilm grown u
microfluidic channels, representative of 3 independent assays, are shown. C
presence (◆) of 100 μM virstatin. Analyse by the Bioflux 200 (Fluxion) softw
(from 0-24 h).baumannii clinical isolates, among which multidrug-
resistant (MDR) and extensively drug-resistant (XDR)
strains [2,17]. Nineteen clinical isolates formed biofilm on
solid support and the remaining 19 isolates had the ability
to form a pellicle [18]. Determination of MICs of virstatin
(4-[N-(1,8-naphthalimide)]-n-butyric acid; Bachem, Weil
am Rhein, Germany) solubilized in dimethyl sulfoxide
(DMSO, Sigma, Saint Louis, USA) was performed by the
microdilution method as described by Wiegand et al. [19].
Virstatin effect on biofilms formed in static mode
A. baumannii biofilms were grown on 24-wells plates in
Mueller Hinton (MH) broth with or without virstatin
added at 20, 50 or 100 μM using DMSO as control.
Plates were incubated for 24 h at 37°C without shaking.
Attached cells were quantified by the protocol described
by O’Toole and Kolter [20] or counted after their de-
tachment by sonication. 25 μL were plated on MH agar
and Colony Forming Units (CFU) were counted after
24 h of additional growth at 37°C. For testing the disper-
sing effect of virstatin, biofilms were grown for 24 h then= 10 h T= 20 h
Without 
virstatin 
With 100 µM 
virstatin 
ibition effect on A. baumannii ATCC 17978 biofilm development in
of different concentrations of virstatin (and DMSO as control)
ed in triplicate and results are presented as (mean ± standard error of
nder flow shear (1 dyn/cm2) in Bioflux system: typical images of the
- Kinetic of biofilm formation under flow shear in absence (●) or in
are give an average value of coverage (μm2) depending on time
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(from 25 to 400 μM). Attached cells were similarly quan-
tified after 24 h of additional growth.
All experiments were performed at least in triplicate.
One way ANOVA was used to assess significant diffe-
rences between a biofilm growth with and without virsta-
tin. All data were statistically analyzed using Prism Graph
Pad 5.
Virstatin effect on biofilms formed in dynamic mode
The effect of virstatin on biofilms formed in dynamic
mode was estimated with the BioFlux device (Fluxion Bio-
sciences, South San Francisco, CA) as described by Benoit
et al. [21] with some modifications. This system consists
of a network of microfluidic laminar flow channels in
which the growth of biofilms is controlled by shear force.
The microfluidic channels (depth, 70 μm; width, 370 μm
in PDMS : PolyDiMéthylSiloxane) were wetted with MH
medium and inoculated with 107 CFU.mL−1 of A. bau-
mannii ATCC 17978 or of the other 39 strains. Following
1 h of incubation for cell attachment at 37°C, 1 mL fresh
MH broth containing or not 100 μM virstatin was
pumped at a flow rate of 0.3 dyn/cm2 from inlet wells
through the channels to outlet wells. To obtain images,
A. baumannii strains were grown for 24 h with a flow rate
of 1 dyn/cm2. During biofilm formation, images were
obtained using an inverted video-microscope (Leica DM
IRBE), a digital camera (CoolSNAP Fx), and treated by
Metamorph 7.0 software. Biofilm quantification was per-
formed by image analysis using the Bioflux 200 software
and the ‘area coverage’ module in ‘greyscale’ mode. The
amount of sessile bacterial covering the flow cells was
estimated in a defined and representative window, by an
average value of coverage (μm2) depending on time (from
0-24 h). These values were then compared in absence or
presence of 100 μM virstatin.Figure 2 Virstatin activity on biofilm formation by A. baumannii clinic
presence of 100 μM virstatin compared to biofilm formation without
virstatin. A. baumannii strains forming biofilm on solid supports in black baMotility experiments
Motility of all A. baumannii strains was tested on poly-
styrene Petri dishes containing 10 g/L tryptone, 5 g/L
NaCl with 0.3% agar (TSA; Difco) supplemented with
100 μM of virstatin or with the same volume of DMSO
and incubated at 37°C overnight [22].
Atomic force microscopy (AFM)
A. baumannii ATCC 17978 pellicles were transferred to
collodion-coated glass slides after 8 h growth in MH broth
supplemented or not with 100 μM of virstatin [11]. AFM
imaging was performed as described in Marti et al. [11].
Results
Virstatin effect on A. baumannii growth in planktonic
mode
We first examined the toxicity of virstatin on planktoni-
cally growing A. baumannii ATCC 17978 by generating
growth curves with and without this compound and by
counting CFU after addition of different concentrations
of virstatin (Additional file 1: Figure S1-A&B). Neither
virstatin nor its solvent (DMSO) inhibited A. baumannii
growth at concentrations used in next steps of this
study. The MIC of virstatin was finally measured at
1.6 mM.
Virstatin effect on A. baumannii sessile bacteria
To investigate the preventing effect of virstatin on bio-
film growth in static mode, we measured A. baumannii
ATCC 17978 biofilm production at varying virstatin con-
centrations. This quantitative determination was moni-
tored by crystal violet colorimetric assay. Figure 1A shows
clearly that virstatin exhibited an anti-biofilm activity,
which was optimal for 100 μM with 38% biofilm forma-
tion inhibition. These data were confirmed by bacterial
counting within the biofilms depending on virstatinal isolates: Percentages measured the 24 h-biofilm formation in
virstatin (but DMSO as control). 100% denoted no activity of
rs (■), strains forming pellicle in dark grey bars ( ).
Figure 3 (See legend on next page.)
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Figure 3 Virstatin affects bacterial motility and pili production. A&B- Plates of motility of A. baumannii ATCC 17978 strain in presence (B) or
absence (A) of virstatin in semi-solid 0.3% TSA after 24 h growth at 37°C. Typical plates are shown. The diameter of the motility zone decreased when
medium is supplemented with 100 μM virstatin. The experiments were performed in triplicate. C-F - AFM images of A. baumannii ATCC 17978 water-
facing side pellicles after 8 h growth: C&E without virstatin; D&F with 100 μM virstatin. Topographic representation using an uncommon scale made to
emphasize the bacterial pili and the ‘EPS’ (extrapolymeric substances) surrounding layer.
Nait Chabane et al. BMC Microbiology 2014, 14:62 Page 5 of 7
http://www.biomedcentral.com/1471-2180/14/62concentrations (Additional file 1: Figure S1-B). We then
examined the dispersing effect of virstatin on preformed
biofilms. After growth for 24 h, biofilms were challenged
by different concentrations of virstatin. Additional file 2:
Figure S2 shows slight biofilm dispersion (12% for 400 μM)
whatever the virstatin concentration. Therefore, virstatin
exerted a marked inhibitory effect on A. baumannii biofilm
formation but a weak dispersing effect on preformed
biofilms.
We also investigated the effect of virstatin on biofilms
formed in dynamic mode under flow shear, using the
Bioflux microfluidic device. Figure 1B shows light micro-
graphs taken from 0 to 24 h after the flow was initiated in
the presence or absence of 100 μM virstatin. At 6 h, the
micrographs showed a reduction of biofilm formation
within the microfluidic channel irrigated by broth en-
riched in virstatin. After 20 h, in absence of virstatin, the
channel was nearly filled by biofilm, whereas broth loaded
with virstatin could still freely flow through the channel.
The Figure 1C showed the kinetic of biofilm formation
within the channels for both conditions. It clearly demon-
strated that virstatin induced a time lag of nearly 10 hours
for biofilm formation and that the biofilm production is
reduced after 24 h. These data confirmed an antibio-
film action of virstatin within the first steps of biofilm
formation.
Virstatin effect on biofilms formed by clinical isolates
To assess more broadly the anti-biofilm activity of vir-
statin, we tested this molecule on different A. baumannii
clinical isolates as well as on the two reference strains.
We examined a panel of 20 isolates forming pellicle and
20 other strains forming only biofilm on solid support
[18]. As shown by Figure 2, 70% of clinical isolates pre-
sented at least a 10% decrease in their ability to form a
biofilm. This decrease reached more than 65% for
100 μM virstatin. It should be noticed that the activity of
virstatin was more marked on strains forming pellicle
(75% of strains with a decrease from 10 to 65%) than on
strains forming only biofilm on solid support (65% of
strains with a decrease from 10 to 47%). The activity of
virstatin was also examined on biofilms grown in dy-
namic mode. If all the tested strains were able to develop
a biofilm in dynamic growth mode, virstatin could in-
duce a time lag only for 60% of strains (Additional file 3:
Table S1) and its activity was also more marked onstrains forming pellicle (75%) than on strains forming
biofilm on solid support (45%).
Virstatin affects bacterial motility and pili production
As virstatin may affect pili production, we performed mo-
tility assays. 0.3% TSA plates containing or not 100 μM
virstatin were inoculated by A. baumannii ATCC 17978
[12]. Figure 3A & B shows that virstatin significantly
inhibited bacterial migration. This motility assay was per-
formed for all the strains (Additional file 3: Table S1) and
the data showed that over the 30 strains that were mobile,
60% underwent a decrease of their motility.
In order to check the presence of pili after virstatin
action, the pellicles of A. baumannii ATCC 17978 were
examined by AFM. In absence of virstatin, observation of
the water-facing side of the pellicles revealed the signifi-
cant presence of pili (0.5 to 2 μm in length) around bac-
teria, which were located on the border of the colonies
(Figure 3C). In contrast when bacteria grew with virstatin,
the amount of pili drastically decreased (Figure 3D).
Moreover, we observed a layer surrounding bacteria, the
average height and width of which were greater in pre-
sence (height: 100 nm, width: 1–1.5 μm) than in absence
of virstatin (height: 50 nm, width: 0.1 μm, Figure 3C & D).
This was most likely extrapolymeric substances (EPS)
overproduced in presence of virstatin. At a lower reso-
lution, images showed strong differences between both
pellicles (Figure 3E & F). The pellicle formed in absence of
virstatin was quite dense and was formed of a single bac-
terial layer, giving a colony mean height of (0.20 ± 0.05)
μm. In presence of virstatin, the pellicle appeared less
dense and formed with more than one layer of bacteria. In
this case, the colony was about (0.50 ± 0.05) μm in height.
Discussion
Targeting essential protein-protein interactions in bacterial
function is a very promising but challenging therapeutic
approach which is increasingly developed [14,15]. In this
context, small organic molecules (ring fused 2-pyridones)
were tested as pilicide or curlicide on uropathogenic
Escherichia coli (UPEC) with success. In targeting either
type 1 pili or amyloid fibers biogenesis, these com-
pounds can prevent biofilm formation and attenuate
UPEC virulence [14]. Virstatin is similarly used to de-
crease the expression of T4P which are virulence factors
in V. cholerae [15,16].
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also an interesting antibiofilm activity as it could reduce
by 65% the biofilm production in some A. baumannii clin-
ical isolates and is active on more than 70% of the tested
strains. Virstatin remained also active against biofilms
formed under flow shear inducing clearly a delay of the
development of this type of biofilm. These results are in
favor of its action on pili biogenesis. Indeed, these cell sur-
face appendages are known to be involved in the first
stages of biofilm development promoting, initial adhesion
and surface colonization but also microcolonies formation
[8]. Thus the decrease of virstatin activity at a later phase
of biofilm development (48 h) is not surprising, as pili
expression may not be required. Moreover, the AFM ob-
servations confirmed the hypothesis suggesting an inhi-
bitory effect of virstatin on the biogenesis of pili: they
pointed out a drastic under-production of these appen-
dages in the presence of the molecule (Figure 3C & D).
Finally, motility experiments demonstrated that virstatin
clearly affected the migration of A. baumannii on semi-
solid surface. This motility has been examined by Clemmer
and colleagues [12] who showed that the loss of pilT, a
gene involved in twitching mediated by T4P, resulted in a
54% reduction in motility of non-flagellar A. baumannii. In
addition, AFM micrographs showed the overexpression of
EPS in biofilms grown with virstatin. Recently Wang et al.
[23] demonstrated that if deletion of T4P in Pseudomonas
aeruginosa resulted in a reduction of biofilm biomass in
flow cell and in pellicles, it concomitantly resulted in an
overproduction of the Psl polysaccharide in the micro-
colonies. Overall, these results are in favor of an action of
virstatin on T4P pili biogenesis.Conclusions
The emergence of A. baumannii as one of the most pro-
blematic nosocomial pathogen has made necessary the de-
velopment of new strategies to impair its ability to persist
in hospital environment. Here, we have tested a strategy
based on the prevention of the pili biosynthesis to reduce
the A. baumannii biofilm production. This was successful
with the use of a small organic compound, the virstatin,
which demonstrated an activity on 70% of the clinical iso-
lates with a decrease in biofilm production that could
reach 65%.Additional files
Additional file 1: Figure S1. Virstatin effect on A. baumannii ATCC
17978 growth in planktonic and biofilm modes. A- Growth curves of
A. baumannii in MH broth (☐), MH broth with 0.5% DMSO (volume used
for the addition of 100 μM virstatin) (◇), or MH broth with 100 μM
virstatin (△). B- A. baumannii colony forming units after a 24 h planktonic
(◆) and biofilm (●) growth depending on virstatin concentrations. Curves
are given as an average of 3 replicates.Additional file 2: Figure S2. Dispersing effect of virstatin. Virstatin
added at 100 μM on 24 h preformed biofilms. Quantification of biofilm
biomass was made by crystal violet staining after additional 24 h growth.
“*” for P < 0.05.
Additional file 3: Table S1. Virstatin effect on A. baumannii clinical
isolates.
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